Table 3.
Detection of Likely or Possible ARV Drug Resistance among 51 Study Participantsa
| ARV drug | Evidence of resistance, n (%) |
|---|---|
| NRTI | |
| ABC | 20 (39.2) |
| ddI | 18 (35.3) |
| FTC | 47 (92.2) |
| 3TC | 47 (92.2) |
| d4T | 21 (41.2) |
| TDF | 13 (25.5) |
| AZT | 22 (43.1) |
| NNRTI | |
| DLV | 32 (62.7) |
| EFV | 31 (60.8) |
| NVP | 32 (62.7) |
| PI | |
| NFV | 4 (7.8) |
| IDV | 4 (7.8) |
| LPV | 3 (5.9) |
| ATV | 3 (5.9) |
| SQV | 4 (7.8) |
| RTV | 4 (7.8) |
| FOS | 3 (5.9) |
| TPV | 3 (5.9) |
| APV | 3 (5.9) |
a
The number and percentage (in parentheses) of participants whose testing revealed likely or possible ARV resistance to each antiretroviral (ARV) drug, according to the ViroSeq report; these numbers were combined to indicate the total number and percentage of participants with evidence of ARV drug resistance. ARV drug abbreviations are defined in the Materials and Methods section.